Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604832 · ClinicalTrials.gov registry record · Phase 1
Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture
A Phase 1 study, sponsored by Kalpna Kay Durairaj, MD, FACS.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06604832 is a Phase 1 study that has completed, run by Kalpna Kay Durairaj, MD, FACS. The registered enrollment target is 20 participants.
The verdict
NCT06604832, a Phase 1 study, has completed, sponsored by Kalpna Kay Durairaj, MD, FACS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will: * be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator) * have one treatment session at week 0, and two live assessment visits at weeks 2 and 12 * have their pictures taken at each visit to track progress
Interventions
- DRUG PrabotulinumtoxinA-Xvfs
- DRUG IncobotulinumtoxinA
- DRUG saline solution (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06604832
The ClinicalTrials.gov registry entry for NCT06604832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kalpna Kay Durairaj, MD, FACS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PrabotulinumtoxinA-Xvfs is the first listed.
NCT06604832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06604832 about?
NCT06604832 is a clinical study titled "Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture". The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will: * be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline trea...
What is the current status of trial NCT06604832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-03. Estimated completion is 2025-09-16.
What interventions are being tested in trial NCT06604832?
The interventions under investigation include: PrabotulinumtoxinA-Xvfs (DRUG), IncobotulinumtoxinA (DRUG), saline solution (placebo) (DRUG).
Who is sponsoring clinical trial NCT06604832?
This trial is sponsored by Kalpna Kay Durairaj, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.